Lexeo Therapeutics
Clinical trials sponsored by Lexeo Therapeutics, explained in plain language.
Lexeo Therapeutics
LXEO
NASDAQ
Develops gene therapies for cardiovascular and CNS diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy trial targets rare heart disease in 10 patients Results expected Dec 2026 (estimated) May already have reported ↗
- New study tracks heart disease in rare genetic disorder Results expected Sep 2027 (estimated)